Mark C. McKenna, Chairman, President & CEO at Prometheus Biosciences, Inc. (RXDX), sold 25,000 shares at $118.99 ($3.0M) on 2023-01-17, disclosed to the SEC on 2023-01-19.
Scheduled sale ($3.0M) by Chairman, President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RXDX | SELL | 2023-03-03 | $1.4M | — | Filing → |
| RXDX | SELL | 2023-02-17 | $7.7M | — | Filing → |
| BHC | SELL | 2019-08-21 | $470K | — | Filing → |